UPSA in the news

Japanese company Taisho Pharmaceutical acquired French pharmaceutical company UPSA from Bristol-Myers Squibb for $1.6 billion in 2019, but UPSA continues to operate in France and is responsible for Efferalgan in the French market.

UPSA uncovered a mass results manipulation scandal involving 178 students and over 500 compromised results.

Upsa, a pharmaceutical company, is committed to manufacturing all its healthcare products in France, including the relocalization of paracetamol production, emphasizing health sovereignty and local integration.

The CEO of Upsa, Isabelle Van Rycke, chaired the jury that selected laureates for the Neo-Aquitaine Economy Awards.

Laure Lechertier from UPSA discusses the importance of not trivializing perimenopause symptoms and advocates for individualized care and open dialogue in pharmacies, highlighting UPSA's non-hormonal supplement, Sérélys PERIMENO, for symptom management.

UPSA and the SUA rugby club confirm their long-standing partnership will continue, despite sponsorship adjustments, relocating UPSA's logo on the team's jersey.

UPSA and Sporting Union Agen Lot-et-Garonne (SUA) are continuing their 30-year partnership with a re-adjusted financial commitment and logo placement on the team's jersey.

UPSA published its 2025 CSR report, detailing progress in sustainable production, territorial anchoring, health initiatives, environmental transition, and social measures, including achieving "Origine France Garantie" and B Corp certifications.

UPSA will produce two new drugs in Agen in exchange for a two-year price freeze on its paracetamol, securing essential medicine production in France.

UPSA, a healthcare products manufacturing company, is working towards making its Efferalgan paracetamol 100% French by 2027 through domestic sourcing of its active ingredient, supported by government agreements and ongoing quality and sustainability efforts.

Upsa, a French pharmaceutical company, is advocating for a price increase on paracetamol to support the higher cost of domestic production and ensure sanitary sovereignty.

The French government plans to reduce paracetamol prices by 13% for manufacturers by 2027, sparking strong opposition from Upsa and Opella, who have invested heavily in domestic production and argue it contradicts relocation efforts.

The French government's plan to reduce paracetamol prices by 13% is alarming pharmaceutical companies like UPSA, who are trying to re-establish domestic production, leading to a conflict between cost-cutting and supporting national industry.

UPSA was recognized for its strategic commitment to French manufacturing and its role in health sovereignty.

Middle school students in the Departmental Youth Council created 'La Bulle' relaxation rooms to support peer mental health in schools.

Agen's local government is expanding public health and mental health initiatives across 44 municipalities to combat medical desertification.

Local government and healthcare partners are expanding mental health services and early intervention programs for vulnerable youth in the Lot-et-Garonne region.

UPSA will produce French-made paracetamol starting in 2027, but is prohibited from labeling it "made in France" due to French regulations against advertising medicines.

Upsa will launch fully French-manufactured paracetamol in 2027 while facing regulatory disputes over pricing and 'Made in France' labeling.

Upsa and Opella are navigating a strategic shift toward domestic paracetamol production while facing economic challenges due to low drug pricing and declining market volumes.